Enrolling By Invitation PHASE3 INTERVENTIONAL 1-arm NCT05967351

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study (EXPEDITION)

A Phase 3, Multinational, Long-term Follow-up Study to Evaluate Safety and Efficacy in Subjects Who Have Previously Received SRP-9001 in a Clinical Study

Sponsor: Hoffmann-La Roche

Conditions Duchenne Muscular Dystrophy

Interventions delandistrogene moxeparvovec

Updated 15 times since 2023 Last updated: Feb 4, 2026 Started: Sep 27, 2023 Primary completion: Oct 31, 2033 Completion: Oct 31, 2033

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Duchenne Muscular Dystrophy and is currently ongoing. Hoffmann-La Roche leads this study, which shows 15 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

15 versions recorded

Feb 2026 — Present [monthly]

Enrolling By Invitation PHASE3
Sep 2025 — Feb 2026 [monthly]

Enrolling By Invitation PHASE3
Feb 2025 — Sep 2025 [monthly]

Enrolling By Invitation PHASE3
Jan 2025 — Feb 2025 [monthly]

Enrolling By Invitation PHASE3
Dec 2024 — Jan 2025 [monthly]

Enrolling By Invitation PHASE3

▶ Show 10 earlier versions

Nov 2024 — Dec 2024 [monthly]

Enrolling By Invitation PHASE3
Oct 2024 — Nov 2024 [monthly]

Enrolling By Invitation PHASE3
Sep 2024 — Oct 2024 [monthly]

Enrolling By Invitation PHASE3
Jul 2024 — Sep 2024 [monthly]

Enrolling By Invitation PHASE3
Jun 2024 — Jul 2024 [monthly]

Enrolling By Invitation PHASE3
May 2024 — Jun 2024 [monthly]

Enrolling By Invitation PHASE3
Mar 2024 — May 2024 [monthly]

Enrolling By Invitation PHASE3
Jan 2024 — Mar 2024 [monthly]

Enrolling By Invitation PHASE3
Nov 2023 — Jan 2024 [monthly]

Enrolling By Invitation PHASE3

Status: Not Yet Recruiting → Enrolling By Invitation
Sep 2023 — Nov 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche
Sarepta Therapeutics, Inc.

Data source: Sarepta Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Baltimore, United States , Boston, United States , Chicago, United States , Columbus, United States , Dallas, United States , Durham, United States , Esplugues de Llobregat, Spain , Essen, Germany , Gainesville, United States and 28 more locations